Search Results

You are looking at 191 - 200 of 858 items for :

  • Refine by Access: All x
Clear All
Full access

Acute Myeloid Leukemia

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, and Eunice S. Wang

and risk of relapse. The second objective focuses on patient-specific factors, including comorbid conditions that may affect an individual's ability to tolerate chemotherapy. Both disease-specific and individual patient factors are considered in

Full access

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz, Mary A. Dwyer, and Hema Sundar

longer median relapse-free survival (RFS; not reached vs 20 months; P <.0001) compared with interferon-alfa; the median follow-up was 57 months. 21 After a median follow-up of 9.3 years, estimated 5- and 10-year overall survival (OS) rates for patients

Full access

Hodgkin Lymphoma

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Lawrence Weiss, Jane N. Winter, and Joachim Yahalom

revised system, response is categorized as complete response, partial response, stable disease, relapsed disease, or progressive disease. Diagnosis Fine needle aspiration alone is generally insufficient for initial diagnosis. Although it is widely

Full access

The Rapid Evolution of Novel Therapies in Multiple Myeloma

Kenneth C. Anderson

-MM response may be able to overcome the ongoing genetic Table 1. Novel FDA-Approved Agents in Myeloma and epigenetic events underlying progression and relapse of disease. Clinical and regulatory strategies have already derived clinical trials

Full access

Non-Hodgkin’s Lymphomas, Version 2.2014

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar

or t(14,18), as mentioned previously. 21 , 23 , 24 Pediatric FL without BCL2 rearrangements tend to be associated with localized disease and have an indolent course and favorable prognosis, with only rare instances of disease progression or relapse

Full access

Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

considered whether EFS or OS provides a more clinically meaningful endpoint for improvement. After careful deliberation, the committee determined that avoiding relapses should take top priority for subgroups with expected EFS <75% to 80%, because (1) the

Full access

Real Personalized Medicine

James O. Armitage, William C. Wood, and Dan L. Longo

overall survival might eventually alter in favor of the group that received radiotherapy as a result of eventual death from lymphoma for some of the patients who experienced relapse, or may show an advantage for no radiotherapy because of the eventual

Full access

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Timothy Gilligan, Daniel W. Lin, Rahul Aggarwal, David Chism, Nicholas Cost, Ithaar H. Derweesh, Hamid Emamekhoo, Darren R. Feldman, Daniel M. Geynisman, Steven L. Hancock, Chad LaGrange, Ellis G. Levine, Thomas Longo, Will Lowrance, Bradley McGregor, Paul Monk, Joel Picus, Phillip Pierorazio, Soroush Rais-Bahrami, Philip Saylor, Kanishka Sircar, David C. Smith, Katherine Tzou, Daniel Vaena, David Vaughn, Kosj Yamoah, Jonathan Yamzon, Alyse Johnson-Chilla, Jennifer Keller, and Lenora A. Pluchino

, large-scale follow-up studies have historically used tumor relapse rather than tumor-specific survival to validate the relevance of pathologic parameters used for staging. 12 However, the association of hilar soft tissue and epididymal invasion with

Full access

“Coming Full Circle”: Reintroduction of Radiotherapy Delaying Chemotherapy Followed by Craniospinal Radiotherapy for Infants With Medulloblastoma

Nicholas G. Gottardo

craniospinal irradiation (CSI) was introduced in the 1950s to prevent the inevitable metastatic relapses throughout the central nervous system (CNS) that many patients sustained, cementing this modality as the backbone of medulloblastoma therapy. For children

Full access

Oncology Research Program

enzalutamide, a potent androgen receptor (AR) antagonist, in the treatment of patients with mantle cell lymphoma (MCL) that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Preclinical studies